Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Immunomodulatory Therapy for FL: The R-Squared Regimen

Further Considerations for Relapsed/Refractory FL 

Treatment Approaches to Relapsed Refractory FL

Optimizing Frontline Therapy and Maintenance in FL

Frontline Treatment Approaches to Follicular Lymphoma 

FL: Monitoring to Initiate Therapy and Gauge Response

Risk Stratification and Outcomes in Follicular Lymphoma 

Diagnosis and Staging for Follicular Lymphoma

The European Commission has approved the bevacizumab biosimilar ABP 215, for the treatment of patients across several tumor types.

Bevacizumab Biosimilar Approved in Europe

FDA Approvals in GBM, Biosimilar in Breast Cancer and Gastric/GEJ Cancer, and Biomarker Assay

The FDA has approved the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst), which now has has approved indications for HER2-positive patients with breast or metastatic gastric or gastroesophageal junction adenocarcinoma.

FDA Approves Trastuzumab Biosimilar

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of the bevacizumab biosimilar ABP 215 for the treatment of patients across several tumor types.

Bevacizumab Biosimilar Nears European Approval

Follicular Lymphoma: Audience Q&A

Follicular Lymphoma: Complexities in Combinations

Follicular Lymphoma: Considering All Novel Agents

FL: The Impact of Data from Clinical Trials

Follicular Lymphoma: Challenges in Moving Forward

Follicular Lymphoma: Optimizing Copanlisib

Follicular Lymphoma: Defining Copanlisib

Follicular Lymphoma: Overview of Treatment Options

 Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Biosimilars

Biosimilars | Specialty